Application effect of DUR and DUE in the evaluation of drug use in patients with community acquired pneumonia
GU Man-hua1 GUO Hua-chun2 HUANG Jun-qing3
1.Department of Pharmacy,People′s Hospital of Tianhe District of Guangzhou City,Guangdong Province,Guangzhou 510000,China;
2.Department of Pharmacy,Tianyuan Street Community Health Service Center of Tianhe District of Guangzhou City,Guangdong Province,Guangzhou 510000,China;
3.Department of Pharmacy,Huagong Community Health Service Center of Wushan Street of Tianhe District of Guangzhou City,Guangdong Province,Guangzhou 510000,China
Abstract:Objective To evaluate the application effect of DUR and DUE in the evaluation of drug use in patients with community acquired pneumonia.Methods 107 patients with community acquired pneumonia treated in Department of Respiration of People′s Hospital of Tianhe District in Guangzhou City from January 2015 to August 2016 were comprehensively analyzed by DUR and DUE.Results A total of 21 antimicrobial agents were used in the treatment of patients,and drugs DUI of 5 cases were more than 1,which were Cefuroxime Sodium,Ceftazidime,Amoxicillin Dispersible Tablets,Itraconazole Capsules and Cefepime.The evaluation results showed that prescription were too large and drug used were irrational.7 patients had adverse drug reactions in the process of hospitalization,96.3%of the patients showed obvious improvement after treatment.Another 4 patients abandoned hospitalization.Conclusion The combined used of DUR and DUE can evaluate the use of antimicrobial agents in primary hospitals more comprehensively,discover unreasonable drug use,promote the management of drug resources,and promote the establishment and perfection of hospital drug system.
古满花;郭华春;黄军清. DUR与DUE方法在社区获得性肺炎患者用药情况评价中的应用效果[J]. 中国当代医药, 2017, 24(5): 149-151.
GU Man-hua;GUO Hua-chun;HUANG Jun-qing. Application effect of DUR and DUE in the evaluation of drug use in patients with community acquired pneumonia. 中国当代医药, 2017, 24(5): 149-151.
Tan J,Zhou J,Zhao P,et al.Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs[J].Clin Rheumatol,2012,31(8):1169-1175.